Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569524 | 0.86 | ALDH1A1 (0.51) | KCNJ11ALDH1A1GAAKDM4ES1PR1 | |
| SCHEMBL15569620 | 0.85 | KCNJ11 (0.40) | KCNJ11ALDH1A1GAAKDM4ECSF1R | |
| SCHEMBL28305748 | 0.79 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4ESGMS2 | |
| SCHEMBL2521895 | 0.79 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4ESGMS2 | |
| SCHEMBL15569636 | 0.78 | SGMS2 (0.40) | KCNJ11ALDH1A1KDM4ECSF1RSGMS2 | |
| SCHEMBL15569998 | 0.78 | CYP2A6 (0.42) | KCNJ11ALDH1A1GAAKDM4ECSF1R | |
| SCHEMBL15569829 | 0.77 | CSF1R (0.45) | KCNJ11ALDH1A1GAAKDM4ECSF1R | |
| SCHEMBL15570279 | 0.75 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4ECSF1RSGMS2 | |
| SCHEMBL15570126 | 0.74 | SGMS2 (0.38) | ALDH1A1GAAKDM4EEGFRCSF1R | |
| SCHEMBL15569879 | 0.73 | EGFR (0.41) | KCNJ11KDM4ES1PR1S1PR3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2888232-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014029726-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | TP53, RB1, HCCS | KCNJ11 2883/4885ALDH1A1 401/4885GAA 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.